AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01766284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRIS 1300e
Description: Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
Study NCT03415269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol Hydrochloride
Description: single lozenge of 20mg ambroxol
Study NCT04055519 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses
Study NCT04055519 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses
Study NCT04055519 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Multi-purpose disinfection solution
Description: Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
Study NCT01939392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation (OneShot™ Renal Denervation System)
Study NCT03360968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Variable-PS
Description: Variable-PS mode switched on for 1 hour
Study NCT03360968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPN-CPAP/PS
Description: SPN-CPAP/PS mode switched on for 1 hour
Study NCT02298491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: 80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
Study NCT03090295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palpation and Accuro
Description: Identify placement for spinal
Study NCT01067547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose.
Description: The total dose of iron sucrose given will be individualised by calculating their iron deficit.
Study NCT01067547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: 300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
Study NCT04153214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycling
Description: Participants will have a portable pedal machine under their desk and will use it 60minutes per day
Study NCT04153214 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cycling
Description: Participants will have a portable pedal machine under their desk and will use it 60minutes per day
Study NCT02639533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150 mg PO, single dose.
Study NCT02699788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifunction Cardiogram
Study NCT01781169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplementation of vitamin D
Description: Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.
Study NCT02376283 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prasugrel
Study NCT02376283 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Study NCT02376283 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ticagrelor
Study NCT02639533 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
Study NCT02284672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02284672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT03920072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Burosumab
Description: Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL
Study NCT03582228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Envrionment for Social Communication
Description: Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~* 15 minutes- Social support group (guided discussion of experiences related to weekly topic)~* 20 minutes- Didactic instruction~* 15 minutes- Role playing~* 10 minutes- Debriefing and group feedback
Study NCT03501771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Disposable acupuncture needles will be inserted into acupoints (BL23, BL25, BL40) bilaterally for a depth of 10-30 mm
Study NCT04872530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pea-protein concentrate
Description: Pea-protein concentrate
Study NCT04872530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fava-bean protein concentrate
Description: Fava-bean protein concentrate
Study NCT04872530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chickpea protein concentrate
Description: Chickpea protein concentrate
Study NCT04872530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red lentil protein concentrate
Description: Red lentil protein concentrate
Study NCT04872530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-essential amino acid blend
Description: Non-essential amino acid blend
Study NCT04872530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein concentrate
Description: Whey protein concentrate
Study NCT03787563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herbal Tea
Description: All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.
Study NCT03787563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tea
Description: Similar looking inert placebo tea.
Study NCT00079131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00079131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00079131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01392521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib + Refametinib (BAY86-9766)
Description: Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
Study NCT01392521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib + Refametinib (BAY86-9766)
Description: Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
Study NCT00084461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT00084461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02891616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study NCT02891616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography-computed tomography
Study NCT02891616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorothymidine
Study NCT02891616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography-magnetic resonance imaging
Study NCT02982512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Administration of dexmedetomidine a different concetrations
Study NCT00728767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.~The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.~The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.~Employees had been instructed to ask these questions during the intervention: What are you already doing to restrain your drinking? And What can you do more?
Study NCT00728767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
Study NCT00245219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
Study NCT00245219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
Study NCT04599179 — intervention group
Intervention type: DEVICE
Intervention: self-expandable metal stent
Description: self-expandable metal stent endoscopic positioning
Study NCT02022176 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose Uptake
Description: Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
Study NCT01636661 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation- non-invasive brain stimulation
Study NCT01636661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation- non-invasive brain stimulation
Study NCT00873639 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
Study NCT00873639 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
Study NCT03379883 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pulsed radiofrequency (P-RF)
Description: Intra articular RF~Insertion of the RF cannula within the joint. The recommended parameters are a pulse width of 20 msec and a rate of 2 Hz at 42°C for 10min.~Genicular nerve RF ablation.~The RF probe will be placed. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of \< 0.6 V
Study NCT03379883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP)
Description: Under ultrasound guidance while the patients in a sitting position. In total, 3 to 8 mL of PRP will be injected via the inta-articular route
Study NCT02022176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Uptake
Description: Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
Study NCT02022176 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resting metabolic rate
Description: Resting metabolic rate is measured by indirect calorimetry after an over-night fast
Study NCT02022176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting metabolic rate
Description: Resting metabolic rate is measured by indirect calorimetry after an over-night fast
Study NCT02022176 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nitrite infusion
Description: Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
Study NCT02022176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitrite infusion
Description: Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
Study NCT03248700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin A tracer
Description: A stable isotope tracer of vitamin A was given orally.
Study NCT01436162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
Study NCT01436162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + Placebo
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Study NCT02002585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
Study NCT01845298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg
Description: The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
Study NCT02417298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
Study NCT02417298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
Study NCT02080663 — intervention group
Intervention type: PROCEDURE
Intervention: Proximal row carpectomy
Study NCT03833518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation using motorized glove for stroke and spinal cord injury
Description: Individuals with hand impairment due to stroke or spinal cord injury will wear a motorized glove (Gloreha Sinfonia), or exoskeleton, as part of a rehabilitation protocol to improve dexterity. For each exercise, participants will attempt to do the action, receiving assistance as necessary via powered motors that can move each finger through its passive range of motion based on the current and target position.
Study NCT03833518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional MRI for stroke and spinal cord injury
Description: All participants will undergo 3 functional MRI's (fMRI's), two at the beginning of the experiment to document brain activity related to movement intention and ability to sense movement. A third MRI will be performed after the rehabilitation is completed to document the change in brain activity related to movement intention and ability to sense movement.
Study NCT03833518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury
Description: Stimulation of the nervous system may be performed using a magnetic stimulator. TMS of the central nervous system is optional. Whether or not a participant undergoes TMS will depend upon their consent, their eligibility for TMS (i.e. no seizure history), and their neurological response to TMS.
Study NCT01077154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously for up to 5 years
Study NCT01077154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered subcutaneously for up to 5 years
Study NCT05740995 — intervention group
Intervention type: DRUG
Intervention: neoadjuvant anti-PD-1 plus chemotherapy
Description: Patients will be given preoperative treatment as below once recruited:~1. Chemotherapy is delivered and composed of two cycles of Nab-paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 3 weeks;~2. PD-1 antibody is delivered 200 mg (iv, in 30 minutes) every 3 weeks;~3. After neoadjuvant therapy of 3-4 cycles, esophagectomy is performed. We advise starting 4 cycles of identical chemoimmunotherapy in 6w after surgery.
Study NCT03540043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of Placebo
Description: Botanical Drug Phase 2 clinical study
Study NCT03540043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of PUR0110 (Thykamine) 0.05%
Description: Botanical Drug Phase 2 clinical study
Study NCT03540043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of PUR0110 (Thykamine) 0.1%
Description: Botanical Drug Phase 2 clinical study
Study NCT03540043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of PUR0110 (Thykamine) 0.25%
Description: Botanical Drug Phase 2 clinical study
Study NCT02555241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mand Training
Description: The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
Study NCT02555241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Matrix
Description: The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
Study NCT03537430 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TNT uniportal VATS mediastinal tumor resection
Description: TNT uniportal video-assisted thoracoscopic surgery refers to the use of conventional uniportal video-assisted thoracoscopic surgery, the use of laryngeal mask anesthesia instead of tracheal intubation anesthesia, intraoperative catheter was not retained, postoperative chest catheter placement.
Study NCT03537430 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional uniportal VATS mediastinal tumor resection
Description: The surgical procedures followed principles of mediastinal tumor resection，uniportal video-assisted thoracoscopic surgery in mediastinal tumor resection.
Study NCT01802671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment and information
Description: Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
Study NCT01802671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment and information
Description: Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)